Skip to main content

Spotlight

A Closer Look at Size Exclusion Chromatography (SEC) in Bioprocessing

Unleashing the Power of Size Exclusion Chromatography (SEC) in Bioprocessing

Size Exclusion Chromatography (SEC), also known as gel filtration chromatography, is a cornerstone technique in the biopharmaceutical industry, prized for its ability to separate molecules based on their hydrodynamic size without denaturing them.

This non-destructive, high-resolution method plays a pivotal role across various stages of bioprocessing, including:

  • Protein characterization
  • Detection of aggregates and fragments
  • Formulation development and stability studies
  • Regulatory-compliant quality control

Why SEC? A Closer Look at Its Advantages

SEC offers several distinct advantages that make it indispensable for both research and manufacturing: 

  • Preserves Molecular Integrity: Operates under mild conditions, maintaining structural fidelity of biomolecules.
  • High Resolution: Accurately differentiates between monomers, dimers, and aggregates.
  • Reproducibility: Ideal for consistent quantification and longitudinal analysis.
  • Compatibility: Works well with a range of common buffers and detection methods.

Tosoh Bioscience: Setting the Standard in SEC Columns

Tosoh Bioscience provides a suite of advanced SEC columns built for both analytical and preparative needs. These columns offer:

  • High-performance resins with uniform particle size and pore distribution
  • Exceptional lot-to-lot reproducibility ensuring dependable results
  • Scalability from early research to full-scale GMP production
  • Superior resolution even for closely related molecular species

Whether working with monoclonal antibodies (mAbs), recombinant proteins, or viral particles, Tosoh’s SEC columns deliver precision and performance.


A Regulatory Ally for Biopharma

SEC is often included in the critical quality attribute (CQA) panel for product characterization, helping to satisfy regulatory standards with confidence. Tosoh’s offerings support:

  • Accurate aggregation profiling aligned with FDA/EMA expectations
  • Data synergy with light scattering, MS, and other orthogonal techniques
  • Comprehensive validation packages for IND, BLA, and NDA filings

Conclusion: SEC as a Strategic Asset

Far beyond a routine technique, SEC is a strategic enabler in modern biopharmaceutical workflows—bridging research, development, and commercial deployment. By leveraging Tosoh Bioscience’s robust SEC solutions, organizations unlock:

High-precision analytics, regulatory confidence, and faster time-to-market.

Back to top